<DOC>
	<DOCNO>NCT00347672</DOCNO>
	<brief_summary>Avian influenza ( AI ) , bird flu , recently become major health concern Asia part world . The need vaccine prevent spread AI among livestock human sorely need . The purpose study test safety immune response new AI vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Bird Flu Virus Vaccine ( H5N1 ) Healthy Adults</brief_title>
	<detailed_description>AI viruses natural reservoir waterfowl source novel HA NA subtypes introduce human population , potential initiate influenza pandemic . This study evaluate safety immunogenicity live , attenuate recombinant AI virus vaccine , H5N1 ( 6-2 ) AA Ca Recombinant ( A/VietNam/1203/2004 x A/AnnArbor/6/60/Ca ) . Participants study receive one two dos vaccine . There 3 group study : - Group 1 receive two vaccination high dose . - Group 2 receive one vaccination dose in-between low high dos . - Group 3 receive one vaccination low dose . Group 1 enroll first , probably 2006 . Groups 2 3 enroll determine safety review vaccine well-tolerated great 80 % Group 1 participant shed vaccine virus develop specific immune response vaccine . Participation study include hospital stay isolation unit Bayview Medical Center Johns Hopkins University . All participant receive vaccine study entry remain isolation unit minimum 14 day vaccination . A physical exam nasal wash occur daily isolation unit participant discharge hospital . Participants allow leave unit viral culture influenza nasal wash negative least 3 consecutive day begin Day 10 . Blood collection occur study entry , Day 7 , sometime Days 28 35 , sometime Days 56 63 . There two separate hospitalization Group 1 participant . Group 1 participant receive dos vaccine study entry sometime Days 28 35 . A physical exam nasal wash occur daily isolation unit participant discharge hospital . Participants allow leave unit viral culture influenza nasal wash negative least 3 consecutive day begin Day 10 . Blood collection occur 4 5 select timepoints , depend time second vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Available duration trial Willing use acceptable form contraception Clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Medical , workrelated , family problem result alcohol illicit drug use 12 month prior study entry History severe allergic reaction anaphylaxis Current asthma reactive airway disease History GuillainBarre syndrome HIV1 infect Hepatitis C virus infect Positive hepatitis B surface antigen ( HBsAg ) Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day study entry . Participants use topical corticosteroid exclude . Live vaccine within 4 week study entry Killed vaccine within 2 week study entry Absence spleen Blood product within 6 month study entry Current smoker Have travel Southern Hemisphere Asia within 14 day prior study entry Have travel cruise ship within 14 day prior study entry Work poultry industry Investigational agent within 60 day prior study entry , currently participate another investigational vaccine drug trial Allergy egg egg product Purified protein derivative ( PPD ) positive ( positive tuberculosis [ TB ] test ) Family member immunodeficiency Other condition , opinion investigator , would affect participant 's participation study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Bird Flu</keyword>
</DOC>